Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma

Trial Profile

A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUTO-4 (Primary)
  • Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms LibrA T1
  • Sponsors Autolus
  • Most Recent Events

    • 21 Mar 2024 This study has been Discontinued in Spain, according to European Clinical Trials Database record.
    • 01 Jul 2023 This study has been suspended in Spain, According to European Clinical Trials Database.
    • 13 Dec 2022 Results (n=73)presented at the 64th American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top